Streetbeat News

Regulatory

USO

The Organization of the Petroleum Exporting Countries (OPEC) has maintained its global economic growth forecast at 2.6% for 2024 and 2.7% for 2023.

Portfolio Pulse from Bill Haddad

September 12, 2023 | 12:17 pm

NRXS

NeurAxis (NRXS) has announced the publication of a prospective study showing that its product, IB-Stim, improves the quality of life of adolescents with Irritable Bowel Syndrome (IBS).

Portfolio Pulse from Benzinga Newsdesk

September 12, 2023 | 12:15 pm

VST

Vistra Corp. (NYSE:VST) has announced the launch of senior secured notes due 2033 and senior unsecured notes due 2031 in concurrent private offerings to qualified institutional buyers and certain non-U.S. persons. The offerings are pursuant to Rule 144A under the Securities Act of 1933, as amended, and Regulation S under the Securities Act.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2023 | 12:09 pm

NXTC

NextCure, Inc. (NASDAQ:NXTC) has announced the presentation of Phase 2 clinical data demonstrating clinical benefit in patients with advanced, PD-1 axis inhibitor refractory non-small cell lung cancer (NSCLC) treated with a combination regimen of NC318, a Siglec-15 (S15) monoclonal antibody (mAb), and pembrolizumab, an anti-PD-1 antibody.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2023 | 12:07 pm

BOLT

Bolt Biotherapeutics has announced the issuance of a US patent covering Dectin-2-targeting agonist antibodies, including BDC-3042. This patent strengthens the company's intellectual property position.

Portfolio Pulse from Bill Haddad

September 12, 2023 | 12:07 pm

PRCT

Procept Biorobotics has received an Investigational Device Exemption approval from the FDA to investigate the safety and efficacy of Aquablation therapy for prostate cancer.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2023 | 12:03 pm

MNMD

MindMed has completed the enrollment for its Phase 2b trial of MM-120, a drug aimed at treating Generalized Anxiety Disorder (GAD).

Portfolio Pulse from Bill Haddad

September 12, 2023 | 11:37 am

ARQT

Arcutis has submitted a Supplemental New Drug Application to the FDA for its Roflumilast Cream 0.15% for the treatment of atopic dermatitis in adults and children aged 6 years and older.

Portfolio Pulse from Bill Haddad

September 12, 2023 | 11:33 am

BTCUSD

Nassim Nicholas Taleb, author of 'Black Swan', criticized artificial market manipulation, particularly in the Bitcoin market. He highlighted the impact of decreasing trading volumes, stating that it facilitates market manipulation and warned that manipulators would eventually look to exit.

Portfolio Pulse from Benzinga Neuro

September 12, 2023 | 11:30 am

MSFT

VGK

EU antitrust regulators are seeking views on Microsoft's remedies to UK watchdog. This comes after Microsoft's proposed acquisition of Nuance Communications, which raised competition concerns.

Portfolio Pulse from Charles Gross

September 12, 2023 | 11:29 am